Biotechnology
Technology
Health
Kadmon
$2.699876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.
$2.69
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
+$0.12 (4.67%) As of 1:58 PM EDT today
+$0.12 (4.67%) Today
Why Robinhood?
You can buy or sell Kadmon and other stocks, options, ETFs, and crypto commission-free!
About KDMN
Kadmon Holdings, Inc., also called Kadmon, is a biopharmaceutical company, which engages in discovering, developing, and commercializing small molecules and biologics. It focuses on the treatment of autoimmune, inflammatory, and fibrotic diseases. Read More Its products include Ribasphere, RibaPak, Tetrabenazine, Valganciclovir, Abacavir, Entecavir, Lamivudine, and Zidovudine. The company was founded by Steven N. Gordon in September 2010 and is headquartered in New York, NY.
Employees
116
Headquarters
New York, New York
Founded
2010
Market Cap
333.16M
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
412.97K
High Today
$2.71
Low Today
$2.55
Open Price
$2.59
Volume
674.78K
52 Week High
$4.39
52 Week Low
$1.63
Collections
Biotechnology
Technology
Health
Biopharmaceutical
Pharmaceutical
2016 IPO
US
North America
Price Paid on Robinhood
20% Lower
Right Now
52 Week Low
$1.88
Average Price Paid
$3.38
52 Week High
$4.39
KDMN Earnings
-$0.37
-$0.22
-$0.08
$0.07
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Q3 2019
Estimated
—
Actual
Expected Nov 8, After Hours